News

BioTeSys was successfully audited by DkkS to renew the longstanding accreditation according DIN EN ISO/IEC 17025:2005. The new accreditation certificate is granted and the flexible accreditation is approved.

CEO Dr. Bernhardt and his colleagues Mrs. Schoen, Mrs Stoebener and Dr. Reule attended Vitafoods 2017 from May 9th until May 11th. They presented the range of services of BioTeSys and had a lot of interesting discussions about scientific substantiation of NEMs, FSMPs and Co.

Visit us this year at Vitafoods Europe 2017 in Geneva. We welcome you from 9th to 11th of May at the booth H52.

The Analytics Department of the BioTeSys GmbH offers the determination of enzyme activities of neutral lactase activity (NLU) and arylsulfatase (ASU). The validation of the used method is verified by an interlaboratory exchange test including the laboratory DSM Food Specialties.

The BioTeSys GmbH receives the accreditation as research service provider from the French Ministry of Higher Education and Research which enables French companies to claim research efforts as tax deductions. French customers of BioTeSys benefit from the accreditation with a tax relief up to 30 percent of the contract value of the R&D project (Dépenses de recherche).

L'entreprise BioTeSys S.a.r.l. a été accréditée par le Ministère de l'Educa-tion Nationale de l'Enseignement Supérieur et de la Recherche comme prestataire de services en R & D (recherche et développement). Les clients français de BioTeSys pourront bénéficier d’un allègement fiscal allant jusqu'à 30% des dépenses en recherche et développement engagées dans le cadre de leur projet.

Not only BioTeSys contemplate about valid scientific evidendence for EFSA applications.

BioTeSys proclaims that clinical trials with nutritions do not have the same requierements as clinical studies with pharmaceuticals. Only a specialised company can fulfill those requierements

BENEO-Orafti S.A. has gained a positive EFSA evaluation for its prebiotic fibre inulin improving the effect on bowel function by increasing stool frequency without triggering diarrhoea. EFSA’s decision is based on six human intervention studies. The study conducted by BioTeSys – Nutritional CRO (Schulz et al., 2012, unpublished) was used to establish the conditions of use for this health claim.

BioTeSys has been testing nanoparticals with the automated genotoxicity assay FADU since 2013 for the international project. New information on nanoparticle security is available now.